Edwards Lifesciences Corp. is lowering their revenue guidance for 2013 because sales of Sapien transcatheter aortic valve implants are not growing as fast as the company had anticipated a quarter ago. The company has not changed its long-term expectations for the market but says that reimbursement for transcatheter aortic valve replacements in some areas is making it difficult for some hospitals to justify their cost.
“U.S. [transcatheter heart valve] sales are below our expectations, which we believe is primarily the result of evolving economics for some hospitals, and still-developing capacity of both hospitals and their...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?